TIDMINDV
RNS Number : 0587Z
Indivior PLC
12 December 2017
Indivior Announces NDA Acceptance of RBP-7000 Risperidone
Monthly Depot
A Novel Sustained-Release Candidate for Treatment of
Schizophrenia
Slough, UK and Richmond, VA, 12 December 2017 - Indivior PLC
(LON: INDV) (the 'Company') today announces that the U.S. Food and
Drug Administration (FDA) has accepted the New Drug Application
(NDA) for RBP-7000, an investigational, once-monthly injectable
risperidone in the ATRIGEL(R) delivery system for the treatment of
schizophrenia. The NDA, which was submitted on September 28, 2017,
is based on data from the pivotal Phase 3 study assessing clinical
efficacy and safety and from the long-term safety study of
RBP-7000. The FDA has set a PDUFA (Prescription Drug User Fee Act)
target action date of July 28, 2018.
"FDA acceptance of our RBP-7000 NDA is a significant milestone
for Indivior as we expand our treatment portfolio to offer a
meaningful therapeutic option to help address non-compliance with
medication administration in the treatment of schizophrenia," said
Christian Heidbreder, Ph.D., Chief Scientific Officer of Indivior.
"We look forward to closely working with the Agency during the
review process to support the approval of RBP-7000 and to provide
both physicians and patients this innovative treatment option."
This NDA submission includes the results from the pivotal Phase
3 study (RB-US-09-0010) assessing the efficacy and safety of
RBP-7000 and an open-label, long-term safety study (RB-US-13-0005).
In the pivotal randomized, double-blind, placebo-controlled study,
RBP-7000 demonstrated statistically significant clinical
improvement compared to placebo based on changes in mean Positive
and Negative Syndrome Scale (PANSS) total and Clinical Global
Impression-Severity of Illness (CGI-S) scores at 8 weeks.
About RBP-7000
RBP-7000 IS AN INVESTIGATIONAL PRODUCT WHOSE SAFETY AND EFFICACY
IS CURRENTLY UNDER REVIEW BY THE U.S. FOOD AND DRUG
ADMINISTRATION.
RBP-7000 is a novel extended-release product using the
ATRIGEL(R) delivery system for the subcutaneous (SC) administration
of risperidone once monthly for the treatment of schizophrenia.
The results of the pivotal Phase 3 studies to assess the
efficacy, safety and tolerability of RBP-7000 in subjects with
acute schizophrenia were recently published.(1.2)
The most common adverse reactions in clinical trials (reported
in >= 5% and greater than placebo group) were weight increase,
constipation, sedation/somnolence, pain in extremity, back pain,
akathisia, anxiety and musculoskeletal pain. The most common
injection site reactions (>= 5%) were injection site pain,
erythema and induration/nodule.
About Schizophrenia
Schizophrenia is a chronic disorder characterized by a life-long
pattern of acute psychotic episodes superimposed upon chronically
poor psychosocial adjustment. The symptoms can be grouped into four
domains: positive (for example, delusions, hallucinations,
disorganized speech and behavior); negative (for example, social
withdrawal, avolition, blunted effect); cognitive (for example,
impaired sustained attention, executive function and working
memory) and affective (for example, anxiety and depression,
hostility and aggression, increased risk of suicide) symptoms.
These occur in different combinations and to a different degree in
each patient. Given the extensive heterogeneity of symptoms among
individual patients, schizophrenia can be considered a clinical
syndrome rather than a single disease entity. An estimated 23
million people worldwide in 2015 were affected with
schizophrenia.(3)
About Indivior
Indivior is a global specialty pharmaceutical company with a
20-year legacy of leadership in patient advocacy and health policy
while providing education on evidence-based treatment models that
have revolutionized modern addiction treatment. The name is the
fusion of the words individual and endeavour, and the tagline
"Focus on you" makes the Company's commitment clear. Indivior is
dedicated to transforming addiction from a global human crisis to a
recognized and treated chronic disease. Building on its global
portfolio of opioid dependence treatments, Indivior has a strong
pipeline of product candidates designed to both expand on its
heritage in this category and address other chronic conditions and
co-occurring disorders of addiction, including alcohol use disorder
and schizophrenia. Headquartered in the United States in Richmond,
VA, Indivior employs more than 900 individuals globally and its
portfolio of products is available in over 40 countries worldwide.
Visit www.indivior.com to learn more.
Forward-Looking Statements
This announcement contains certain statements that are
forward-looking and which should be considered, amongst other
statutory provisions, in light of the safe harbour provisions of
the United States Private Securities Litigation Reform Act of 1995.
By their nature, forward-looking statements involve risk and
uncertainty as they relate to events or circumstances that may or
may not occur in the future. Actual results may differ materially
from those expressed or implied in such statements because they
relate to future events. Forward-looking statements include, among
other things, statements regarding the Indivior Group's financial
guidance for 2017 and its medium- and long-term growth outlook, its
operational goals, its product development pipeline and statements
regarding ongoing litigation.
Various factors may cause differences between Indivior's
expectations and actual results, including: factors affecting sales
of Indivior Group's products; the outcome of research and
development activities; decisions by regulatory authorities
regarding the Indivior Group's drug applications; the speed with
which regulatory authorizations, pricing approvals and product
launches may be achieved; the outcome of post-approval clinical
trials; competitive developments; difficulties or delays in
manufacturing; the impact of existing and future legislation and
regulatory provisions on product exclusivity; trends toward managed
care and healthcare cost containment; legislation or regulatory
action affecting pharmaceutical product pricing, reimbursement or
access; claims and concerns that may arise regarding the safety or
efficacy of the Indivior Group's products and product candidates;
risks related to legal proceedings; the Indivior Group's ability to
protect its patents and other intellectual property; the outcome of
patent infringement litigation relating to Indivior Group's
products, including the ongoing ANDA lawsuits; changes in
governmental laws and regulations; issues related to the
outsourcing of certain operational and staff functions to third
parties; uncertainties related to general economic, political,
business, industry, regulatory and market conditions; and the
impact of acquisitions, divestitures, restructurings, internal
reorganizations, product recalls and withdrawals and other unusual
items.
Media Contacts
US
IndiviorMediaContacts@indivior.com
+1 804-594-0836
UK
Tulchan Communications
+44 207 353 4200
Investor Contact
Jason Thompson, Indivior
Vice President, Investor Relations
+1 804-423-8916
Jason.thompson@indivior.com
REFERENCES
1. Nasser AF, Henderson DC, Fava M, Fudala PJ, Twumasi-Ankrah P,
Kouassi A, Heidbreder C. Efficacy, safety and tolerability of
RBP-7000 once monthly risperidone for the treatment of acute
schizophrenia: An 8-week, randomized, double-blind,
placebo-controlled, multicenter Phase 3 study. J. Clin.
Psychopharmacology, 2016, 36(2): 130-140.
2. Isitt JJ, Nadipelli VR, Kouassi A, Fava M, Heidbreder C.
Health-related quality of life in acute schizophrenia patients
treated with RBP-7000 once monthly risperidone: An 8-week,
randomized, double-blind, placebo-controlled, multicenter phase 3
study. Schizophr Res., 2016, 174(1-3): 126-131.
3. GBD 2015 Disease and Injury Incidence and Prevalence
Collaborators. Global, regional, and national incidence,
prevalence, and years lived with disability for 310 diseases and
injuries, 1990-2015: a systematic analysis for the Global Burden of
Disease Study 2015. The Lancet, 2016, 388:1545-602
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUUONRBUAUARA
(END) Dow Jones Newswires
December 12, 2017 02:00 ET (07:00 GMT)
Indivior (LSE:INDV)
Historical Stock Chart
From Apr 2024 to May 2024
Indivior (LSE:INDV)
Historical Stock Chart
From May 2023 to May 2024